Resectable Pancreatic Ductal Adenocarcinoma
14 clinical trials · Condition
◉ Watch Resectable Pancreatic Ductal Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer (NCT05055323) | Thomas Jefferson University | 2021-07-29 |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer (NCT04005690) | OHSU Knight Cancer Institute | 2019-08-01 |
| Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (NCT03970252) | Jonsson Comprehensive Cancer Center | 2019-07-24 |
| Nalirinox Neo-pancreas RAS Mut ctDNA Study (NCT04010552) | Fundación de investigación HM | 2019-05-01 |
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (NCT02978547) | British Columbia Cancer Agency | 2019-01-01 |
| A Phase II Study of Neoadjuvant FOLFIRINOX (NCT02178709) | Indiana University | 2014-06-03 |
Track Resectable Pancreatic Ductal Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.